Vortrag am FONDS professionell KONGRESSL&G Pharma Breakthrough UCITS ETF USD Accumulating ETF
| MVD-Fonds Rating | EDA |
|---|---|
  | 76 |
ISIN: IE00BF0H7608 | WKN: A2H9XR
KAG: LGIM Managers (EU)
NAV: 10,79 USD am 27.09.2024
Portfolio
Watchlist
KursalarmChart
Kennzahlen L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF
| 1M | 6M | 1J | 3J | 5J | 10J | Beginn | |
| Performance | -3,30% | +9,34% | +4,42% | -17,78% | +22,82% | - | +9,21% |
| Volatilität | +10,47% | +13,52% | +14,50% | +16,38% | +18,73% | - | +18,50% |
| Sharpe Ratio | -3,44 | +1,19 | +0,07 | -0,59 | +0,05 | - | -0,11 |
| Bester Monat | - | +6,80% | +6,80% | +8,83% | +17,89% | - | +17,89% |
| Schl. Monat | - | -5,20% | -7,27% | -7,27% | -8,09% | - | -14,53% |
| Max. Verlust | -5,12% | -8,65% | -15,51% | -33,45% | -34,14% | - | -34,14% |
Monatsperformance L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF
| 2024 | 2023 | 2022 | 2021 | 2020 | |
| Januar | -5,29% | +4,06% | -5,88% | -0,11% | +1,15% |
| Februar | -1,10% | -4,94% | -1,12% | -3,01% | -1,93% |
| März | -0,15% | -3,02% | +2,29% | -2,51% | -8,09% |
| April | -5,20% | +3,49% | -5,95% | +1,64% | +17,89% |
| Mai | +3,36% | -3,78% | -3,98% | +0,20% | +6,78% |
| Juni | +1,97% | -3,11% | +1,16% | +4,79% | +0,82% |
| Juli | +6,41% | +3,29% | +1,81% | -3,11% | +0,77% |
| August | +6,80% | -2,42% | -3,24% | +3,91% | +4,15% |
| September | -3,06% | -6,09% | -4,21% | -3,51% | -1,52% |
| Oktober | - | -7,27% | +3,13% | +0,71% | -6,22% |
| November | - | +6,58% | +8,83% | -4,07% | +7,42% |
| Dezember | - | +3,64% | +0,68% | +1,63% | +5,48% |
| Gesamt | +2,95% | -10,27% | -7,27% | -3,85% | +27,08% |
Diese Fonds könnten Sie auch interessieren
Vergleichen Sie diese Fonds mit Ihrem ausgewähltem Fonds (L&G Pharma Breakthrough UCITS ETF) oder suchen Sie weitere Top-Fonds zum Thema Aktien (ETF Aktien) weltweit in USD:
Fonds vergleichenWeitere ähnliche Fonds